Prostate cancer (PCa) is the second most common cancer among men worldwide [1]. Due to the subtle nature of early symptoms, most patients are diagnosed at an advanced stage.Androgen deprivation therapy (ADT) remains the cornerstone treatment for locally advanced and metastatic prostate cancer (mPCa) [2]. Although most patients eventually progress to castration-resistant prostate cancer (CRPC), the duration of CRPC progression varies between individuals [3,4]. Accurately predicting CRPC time befo…